{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:15:50Z","timestamp":1792512950651,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The biggest impact on increasing survival for pancreatic cancer has come about by combining surgical resection with systemic chemotherapy. This groundbreaking paradigm has come under increasing scrutiny relating to the choice of adding chemoradiotherapy to chemotherapy versus chemotherapy alone, neoadjuvant versus adjuvant therapy and the optimal regimens. The paradigm has also been challenged in that a distinction needs to be made between \u2018resected\u2019 with \u2018resectable\u2019 pancreatic cancer, since if only the former is considered, this leads to a biased prognostically favourable patient group being analysed. Moreover, the distinction between resectable, borderline resectable and unresectable cancers is claimed to be so unreliable that this classification should be discouraged in favour of upfront chemotherapy for all patients and not necessarily using either FOLFIRINOX or gemcitabine-capecitabine. The results of a series of recent trials including the RTOG0848 trial of adjuvant chemotherapy with or without chemoradiation and the NORPACT-1 trial of neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic cancer have significantly contributed to the clarification of some these questions. The results of long-term follow-up studies of the adjuvant PRODIGE24 trial comparing FOLFIRINOX with gemcitabine and the ESPAC4 trial of gemcitabine-capecitabine versus gemcitabine have also consolidated and expanded the applicability of adjuvant chemotherapy.<\/jats:p>","DOI":"10.1038\/s41416-025-03295-9","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:17:21Z","timestamp":1764861441000},"page":"531-542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer"],"prefix":"10.1038","volume":"134","author":[{"given":"Christoph","family":"Springfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-1196","authenticated-orcid":false,"given":"Thilo","family":"Hackert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7147-5703","authenticated-orcid":false,"given":"Daniel H.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"\u00d6hlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Peccerella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus W.","family":"B\u00fcchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph W.","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6201-7399","authenticated-orcid":false,"given":"John P.","family":"Neoptolemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"3295_CR1","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","volume":"358","author":"JP Neoptolemos","year":"2001","unstructured":"Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576\u201385.","journal-title":"Lancet"},{"key":"3295_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200\u201310.","journal-title":"N Engl J Med"},{"key":"3295_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(01)06666-1","volume":"358","author":"RA Abrams","year":"2001","unstructured":"Abrams RA, Lillemoe KD, Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet. 2001;358:1565\u20136.","journal-title":"Lancet"},{"key":"3295_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2004.11.018","volume":"61","author":"MC Koshy","year":"2005","unstructured":"Koshy MC, Landry JC, Cavanaugh SX, Fuller CD, Willett CG, Abrams RA, et al. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys. 2005;61:965\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3295_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267\u201377.","journal-title":"JAMA"},{"key":"3295_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.bjc.6604838","volume":"100","author":"JP Neoptolemos","year":"2009","unstructured":"Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer. 2009;100:246\u201350.","journal-title":"Br J Cancer"},{"key":"3295_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","volume":"304","author":"JP Neoptolemos","year":"2010","unstructured":"Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073\u201381.","journal-title":"JAMA"},{"key":"3295_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248\u201357.","journal-title":"Lancet"},{"key":"3295_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011\u201324.","journal-title":"Lancet"},{"key":"3295_CR10","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"3295_CR11","doi-asserted-by":"publisher","unstructured":"Hegewisch-Becker S, Kratz-Albers K, Wierecky J, Gerhardt S, Reschke D, Borchardt J, et al. Current treatment landscape of pancreatic cancer patients in a network of office-based oncologists in Germany. Future Oncol. 2022. https:\/\/doi.org\/10.2217\/fon-2022-0141.","DOI":"10.2217\/fon-2022-0141"},{"key":"3295_CR12","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.2217\/fon-2021-1583","volume":"18","author":"M Chase","year":"2022","unstructured":"Chase M, Friedman HS, Joo S, Navaratnam P. Adjuvant and neoadjuvant treatment patterns among resectable pancreatic cancer patients in the USA. Future Oncol. 2022;18:3929\u201339.","journal-title":"Future Oncol"},{"key":"3295_CR13","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1200\/JCO.22.01134","volume":"41","author":"MA Tempero","year":"2023","unstructured":"Tempero MA, Pelzer U, O\u2019Reilly EM, Winter J, Oh DY, Li CP, et al. Adjuvant nab-Paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J Clin Oncol. 2023;41:2007\u201319.","journal-title":"J Clin Oncol"},{"key":"3295_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:987\u20131002.","journal-title":"Ann Oncol"},{"key":"3295_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2013.50.7657","volume":"32","author":"JW Valle","year":"2014","unstructured":"Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504\u201312.","journal-title":"J Clin Oncol"},{"key":"3295_CR16","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022;8:1571\u20138.","journal-title":"JAMA Oncol"},{"key":"3295_CR17","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473\u201381.","journal-title":"JAMA"},{"key":"3295_CR18","first-page":"1240","volume":"43","author":"DH Palmer","year":"2025","unstructured":"Palmer DH, Jackson R, Springfeld C, Ghaneh P, Rawcliffe C, Halloran CM, et al. Pancreatic adenocarcinoma: long-term outcomes of adjuvant therapy in the ESPAC4 phase III trial. J Clin Oncol. 2025;43:1240\u201353.","journal-title":"J Clin Oncol"},{"key":"3295_CR19","unstructured":"Tempero MA, Malafa MP, Benson AB, Cardin DB, Chiorean EG, Chung V, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Version 3.2024, 08\/02\/2024 \u00a9 2024 National Comprehensive Cancer Network\u00ae (NCCN\u00ae), NCCN.org."},{"key":"3295_CR20","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.pan.2018.09.012","volume":"18","author":"D O\u2019Reilly","year":"2018","unstructured":"O\u2019Reilly D, Fou L, Hasler E, Hawkins J, O\u2019Connell S, Pelone F, et al. Diagnosis and management of pancreatic cancer in adults: a summary of guidelines from the UK National Institute for Health and Care Excellence. Pancreatology. 2018;18:962\u201370.","journal-title":"Pancreatology"},{"key":"3295_CR21","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1001\/jamaoncol.2022.4673","volume":"8","author":"M Reni","year":"2022","unstructured":"Reni M, Macchini M, Orsi G. Is the Delphi\u2019s oracle pertinent to patients with resectable and borderline resectable pancreatic ductal adenocarcinoma?. JAMA Oncol. 2022;8:1851.","journal-title":"JAMA Oncol"},{"key":"3295_CR22","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamaoncol.2022.0168","volume":"8","author":"EN Pijnappel","year":"2022","unstructured":"Pijnappel EN, Suurmeijer JA, Koerkamp BG, Kos M, Siveke JT, Salvia R, et al. Consensus statement on mandatory measurements for pancreatic cancer trials for patients with resectable or borderline resectable disease (COMM-PACT-RB): a systematic review and Delphi consensus statement. JAMA Oncol. 2022;8:929\u201337.","journal-title":"JAMA Oncol"},{"key":"3295_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","volume":"272","author":"SA Ahmad","year":"2020","unstructured":"Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine\/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. 2020;272:481\u20136. https:\/\/doi.org\/10.1097\/SLA.0000000000004155.","journal-title":"Ann Surg"},{"key":"3295_CR24","doi-asserted-by":"publisher","first-page":"e087","DOI":"10.1097\/AS9.0000000000000087.","volume":"2","author":"F Giannone","year":"2021","unstructured":"Giannone F, Capretti G, Abu Hilal M, Boggi U, Campra D, Cappelli C, et al. Resectability of pancreatic cancer is in the eye of the observer: a multicenter, blinded, prospective assessment of interobserver agreement on NCCN resectability status criteria. Ann Surg Open. 2021;2:e087. https:\/\/doi.org\/10.1097\/AS9.0000000000000087.","journal-title":"Ann Surg Open"},{"key":"3295_CR25","doi-asserted-by":"crossref","unstructured":"Badgery HE, Muhlen-Schulte T, Zalcberg JR, D\u2019souza B, Gerstenmaier JF, Pickett C, et al. Determination of \u201cborderline resectable\u201d pancreatic cancer\u2014a global assessment of 30 shades of grey. HPB. 2023;25:1393\u2013401.","DOI":"10.2139\/ssrn.4288837"},{"key":"3295_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S2468-1253(22)00393-4","volume":"8","author":"M Reni","year":"2023","unstructured":"Reni M, Orsi G. Lessons and open questions in borderline resectable pancreatic cancer. Lancet Gastroenterol Hepatol. 2023;8:101\u20132.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3295_CR27","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1093\/annonc\/mdx495","volume":"28","author":"M Reni","year":"2017","unstructured":"Reni M, Zanon S, Balzano G, Nobile S, Pircher CC, Chiaravalli M, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 2017;28:2786\u201392.","journal-title":"Ann Oncol"},{"key":"3295_CR28","doi-asserted-by":"publisher","first-page":"LBA4004","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4004","volume":"43","author":"M Reni","year":"2025","unstructured":"Reni M, Macchini M, Orsi G, Procaccio L, Malleo G, Balzano G, et al. Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma. J Clin Oncol. 2025;43:LBA4004.","journal-title":"J Clin Oncol"},{"key":"3295_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Prim. 2016;2:16022.","journal-title":"Nat Rev Dis Prim"},{"key":"3295_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41571-018-0112-1","volume":"16","author":"O Strobel","year":"2019","unstructured":"Strobel O, Neoptolemos J, J\u00e4ger D, B\u00fcchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16:479\u201392.","journal-title":"Nat Rev Clin Oncol"},{"key":"3295_CR31","doi-asserted-by":"publisher","first-page":"e161137","DOI":"10.1001\/jamasurg.2016.1137","volume":"151","author":"MH Katz","year":"2016","unstructured":"Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh RdeW, Collisson E, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016;151:e161137.","journal-title":"JAMA Surg"},{"key":"3295_CR32","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1245\/s10434-012-2809-1","volume":"20","author":"W Hartwig","year":"2013","unstructured":"Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188\u201396.","journal-title":"Ann Surg Oncol"},{"key":"3295_CR33","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1097\/SLA.0000000000004845","volume":"276","author":"T Hank","year":"2022","unstructured":"Hank T, Hinz U, Reiner T, Malleo G, K\u00f6nig AK, Maggino L, et al. A pretreatment prognostic score to stratify survival in pancreatic cancer. Ann Surg. 2022;276:e601\u2013e9.","journal-title":"Ann Surg"},{"key":"3295_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10353-023-00814-x","volume":"56","author":"JP Neoptolemos","year":"2024","unstructured":"Neoptolemos JP, Hu K, Bailey P, Springfeld C, Cai B, Miao Y, et al. Personalized treatment in localized pancreatic cancer. Eur Surg. 2024;56:93\u2013109.","journal-title":"Eur Surg"},{"key":"3295_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add9342","volume":"10","author":"IL Ho","year":"2024","unstructured":"Ho IL, Li CY, Wang F, Zhao L, Liu J, Yen EY, et al. Clonal dominance defines metastatic dissemination in pancreatic cancer. Sci Adv. 2024;10:eadd9342.","journal-title":"Sci Adv"},{"key":"3295_CR36","doi-asserted-by":"publisher","unstructured":"Kalfakakou D, Cameron DC, Kawaler EA, Tsuda M, Wang L, Jing X, et al. Clonal Heterogeneity in Human Pancreatic Ductal Adenocarcinoma and Its Impact on Tumor Progression. bioRxiv [Preprint]. 2025 https:\/\/doi.org\/10.1101\/2025.02.11.637729.","DOI":"10.1101\/2025.02.11.637729"},{"key":"3295_CR37","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/oncolo\/oyae155","volume":"29","author":"GP Botta","year":"2024","unstructured":"Botta GP, Abdelrahim M, Drengler RL, Aushev VN, Esmail A, Laliotis G, et al. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Oncologist. 2024;29:859\u201369. Erratum in: Oncologist. 2024 Nov 4;29:e1630.","journal-title":"Oncologist"},{"key":"3295_CR38","doi-asserted-by":"crossref","unstructured":"Lee B, Tie J, Wang Y, Cohen J, Shapiro JD, Wong R, et al. The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial. J Clin Oncol. 2024;42:107.","DOI":"10.1200\/JCO.2024.42.16_suppl.107"},{"key":"3295_CR39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1097\/SLA.0000000000000814","volume":"261","author":"O Strobel","year":"2015","unstructured":"Strobel O, Hinz U, Gluth A, Hank T, Hackert T, Bergmann F, et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann Surg. 2015;261:961\u20139.","journal-title":"Ann Surg"},{"key":"3295_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/SLA.0000000000001731","volume":"265","author":"O Strobel","year":"2017","unstructured":"Strobel O, Hank T, Hinz U, Bergmann F, Schneider L, Springfeld C, et al. Pancreatic cancer surgery: the new R-status counts. Ann Surg. 2017;265:565\u201373.","journal-title":"Ann Surg"},{"key":"3295_CR41","first-page":"469","volume":"396","author":"W Hartwig","year":"2011","unstructured":"Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011;396:469\u201380.","journal-title":"Ann Surg"},{"key":"3295_CR42","first-page":"245","volume":"5","author":"M Schneider","year":"2021","unstructured":"Schneider M, Hackert T, Strobel O, B\u00fcchler MW. Technical advances in surgery for pancreatic cancer. Br J Surg. 2021;5:245\u201352.","journal-title":"Br J Surg"},{"key":"3295_CR43","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/SLA.0000000000004147","volume":"275","author":"O Strobel","year":"2022","unstructured":"Strobel O, Lorenz P, Hinz U, Gaida M, K\u00f6nig AK, Hank T, et al. Actual five-year survival after upfront resection for pancreatic ductal adenocarcinoma: who beats the odds?. Ann Surg. 2022;275:962\u201371.","journal-title":"Ann Surg"},{"key":"3295_CR44","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/SLA.0000000000002245","volume":"272","author":"G Malleo","year":"2020","unstructured":"Malleo G, Maggino L, Ferrone CR, Marchegiani G, Luchini C, Mino-Kenudson M, et al. Does site matter? Impact of tumor location on pathologic characteristics, recurrence, and survival of resected pancreatic ductal adenocarcinoma. Ann Surg. 2020;272:1080\u20138.","journal-title":"Ann Surg"},{"key":"3295_CR45","first-page":"261","volume":"408","author":"PC M\u00fcller","year":"2023","unstructured":"M\u00fcller PC, M\u00fcller BP, Hackert T. Contemporary artery-first approaches in pancreatoduodenectomy. BJS Open. 2023;408:261.","journal-title":"BJS Open"},{"key":"3295_CR46","first-page":"723","volume":"43","author":"I Tarantino","year":"2017","unstructured":"Tarantino I, Warschkow R, Hackert T, Schmied BM, B\u00fcchler MW, Strobel O, et al. Staging of pancreatic cancer based on the number of positive lymph nodes. Eur J Surg Oncol. 2017;43:723\u201331.","journal-title":"Eur J Surg Oncol"},{"key":"3295_CR47","first-page":"887","volume":"23","author":"P Nitschke","year":"2016","unstructured":"Nitschke P, Volk A, Welsch T, Hackl J, Reissfelder C, Rahbari M, et al. Impact of intraoperative re-resection to achieve R0 status on survival in patients with pancreatic cancer: a single-center experience with 483 patients. Ann Surg Oncol. 2016;23:887\u201393.","journal-title":"Ann Surg Oncol"},{"key":"3295_CR48","first-page":"411","volume":"268","author":"T Hank","year":"2018","unstructured":"Hank T, Hinz U, Tarantino I, Kaiser J, Niesen W, Bergmann F, et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Ann Surg. 2018;268:411\u20137.","journal-title":"Ann Surg"},{"key":"3295_CR49","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","volume":"155","author":"M Bockhorn","year":"2014","unstructured":"Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977\u201388.","journal-title":"Surgery"},{"key":"3295_CR50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/SLA.0000000000005444","volume":"277","author":"T Hackert","year":"2023","unstructured":"Hackert T, Klaiber U, Hinz U, Strunk S, Loos M, Strobel O, et al. Portal vein resection in pancreatic cancer surgery: risk of thrombosis and radicality determine survival. Ann Surg. 2023;277:113\u201321.","journal-title":"Ann Surg"},{"key":"3295_CR51","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.hpb.2017.07.007","volume":"19","author":"T Hackert","year":"2017","unstructured":"Hackert T, Strobel O, Michalski CW, Mihaljevic AL, Mehrabi A, M\u00fcller-Stich BP, et al. The TRIANGLE operation \u2013 radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB (Oxf). 2017;19:1001\u20137.","journal-title":"HPB (Oxf)"},{"key":"3295_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07337-6","volume":"24","author":"P Heger","year":"2023","unstructured":"Heger P, Hackert T, Diener MK, Fei\u00dft M, Klose C, D\u00f6rr-Harim C, et al. Conventional partial pancreatoduodenectomy versus an extended pancreatoduodenectomy (triangle operation) for pancreatic head cancers\u2014study protocol for the randomised controlled TRIANGLE trial. Trials. 2023;24:400.","journal-title":"Trials"},{"key":"3295_CR53","doi-asserted-by":"publisher","unstructured":"Kinny-K\u00f6ster B, Halm D, Tran D, Kaiser J, Heckler M, Hank T, et al. Who do we fail to rescue after pancreatoduodenectomy? Outcomes among >4000 procedures expose windows of opportunity. Ann Surg. 2024. https:\/\/doi.org\/10.1097\/SLA.0000000000006429.","DOI":"10.1097\/SLA.0000000000006429"},{"key":"3295_CR54","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/SLA.0b013e318156eef3","volume":"246","author":"HG Smeenk","year":"2007","unstructured":"Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007;246:734\u201340.","journal-title":"Ann Surg"},{"key":"3295_CR55","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jama.299.9.1019","volume":"299","author":"WF Regine","year":"2008","unstructured":"Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019\u201326.","journal-title":"JAMA"},{"key":"3295_CR56","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","volume":"18","author":"WF Regine","year":"2011","unstructured":"Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup\/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18:1319\u201326.","journal-title":"Ann Surg Oncol"},{"key":"3295_CR57","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/sj.bjc.6605256","volume":"101","author":"H Ueno","year":"2009","unstructured":"Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908\u201315.","journal-title":"Br J Cancer"},{"key":"3295_CR58","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1200\/JCO.2011.38.2960","volume":"30","author":"J Schmidt","year":"2012","unstructured":"Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, Herrmann T, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012;30:4077\u201383.","journal-title":"J Clin Oncol"},{"key":"3295_CR59","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","volume":"35","author":"M Sinn","year":"2017","unstructured":"Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, et al. CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol. 2017;35:3330\u20137.","journal-title":"J Clin Oncol"},{"key":"3295_CR60","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejca.2020.06.032","volume":"138","author":"M Sinn","year":"2020","unstructured":"Sinn M, Liersch T, Riess H, Gellert K, St\u00fcbs P, Waldschmidt D, et al. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib\/placebo in patients with R1 resection of pancreatic cancer - Final results. Eur J Cancer. 2020;138:172\u201381.","journal-title":"Eur J Cancer"},{"key":"3295_CR61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/COC.0000000000000633","volume":"43","author":"RA Abrams","year":"2020","unstructured":"Abrams RA, Winter KA, Safran H, Goodman KA, Regine WF, Berger AC, et al. Results of the NRG oncology\/RTOG 0848 adjuvant chemotherapy question erlotinib + gemcitabine for resected cancer of the pancreatic head: a phase II randomized clinical trial. Am J Clin Oncol. 2020;43:173\u20139.","journal-title":"Am J Clin Oncol"},{"key":"3295_CR62","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1200\/JCO.2024.42.16_suppl.4005","volume":"42","author":"RA Abrams","year":"2024","unstructured":"Abrams RA, Winter KA, Goodman KA, Regine R, Safran H, Berger AC, et al. NRG Oncology\/RTOG 0848: Results after adjuvant chemotherapy +\/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). J Clin Oncol. 2024;42:4005.","journal-title":"J Clin Oncol"},{"key":"3295_CR63","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/jnci\/djn428","volume":"100","author":"R Twombly","year":"2008","unstructured":"Twombly R. Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. J Natl Cancer Inst. 2008;100:1670\u20131.","journal-title":"J Natl Cancer Inst"},{"key":"3295_CR64","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1200\/JCO.2008.17.0811","volume":"26","author":"N Merchant","year":"2008","unstructured":"Merchant N, Berlin J. Past and future of pancreas cancer: are we ready to move forward together?. J Clin Oncol. 2008;26:3478\u201380.","journal-title":"J Clin Oncol"},{"key":"3295_CR65","doi-asserted-by":"crossref","unstructured":"Palmer DH, Jackson RJ, Springfeld C, Hackert T, Michalski CW, Neoptolemos JP. Reply to: adjuvant treatment options and modalities in pancreatic adenocarcinoma: insights from ESPAC4. J Clin Oncol. 2025;43:2229\u201330.","DOI":"10.1200\/JCO-25-00333"},{"key":"3295_CR66","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1053\/j.gastro.2016.02.070","volume":"150","author":"L Seifert","year":"2016","unstructured":"Seifert L, Werba G, Tiwari S, Giao Ly NN, Nguy S, Alothman S, et al. Radiation therapy induces macrophages to suppress t-cell responses against pancreatic tumors in mice. Gastroenterology. 2016;150:1659\u201372.","journal-title":"Gastroenterology"},{"key":"3295_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0577-4","volume":"16","author":"SY Lee","year":"2017","unstructured":"Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY, Kim CH, et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017;16:10.","journal-title":"Mol Cancer"},{"key":"3295_CR68","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41588-022-01134-8","volume":"54","author":"WL Hwang","year":"2022","unstructured":"Hwang WL, Jagadeesh KA, Guo JA, Hoffman HI, Yadollahpour P, Reeves JW, et al. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat Genet. 2022;54:1178\u201391.","journal-title":"Nat Genet"},{"key":"3295_CR69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3295_CR70","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.21.01220","volume":"39","author":"WA Hall","year":"2021","unstructured":"Hall WA, Dawson LA, Hong TS, Palta M, Herman JM, Evans DB, et al. Value of Neoadjuvant radiation therapy in the management of pancreatic adenocarcinoma. J Clin Oncol. 2021;39:3773\u20137.","journal-title":"J Clin Oncol"},{"key":"3295_CR71","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.surg.2023.01.016","volume":"173","author":"A Cucchetti","year":"2023","unstructured":"Cucchetti A, Djulbegovic B, Crippa S, Hozo I, Sbrancia M, Tsalatsanis A, et al. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Surgery. 2023;173:1421\u20137.","journal-title":"Surgery"},{"key":"3295_CR72","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature19823","volume":"538","author":"F Notta","year":"2016","unstructured":"Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016;538:378\u201382.","journal-title":"Nature"},{"key":"3295_CR73","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O\u2019Kane GM, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020;52:231\u201340.","journal-title":"Nat Genet"},{"key":"3295_CR74","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","volume":"184","author":"BT Gr\u00fcnwald","year":"2021","unstructured":"Gr\u00fcnwald BT, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey CW, et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021;184:5577\u201392.e18.","journal-title":"Cell"},{"key":"3295_CR75","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s43018-023-00628-6","volume":"4","author":"X Zhou","year":"2023","unstructured":"Zhou X, An J, Kurilov R, Brors B, Hu K, Peccerella T, et al. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Nat Cancer. 2023;4:1362\u201381.","journal-title":"Nat Cancer"},{"key":"3295_CR76","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"Springfeld C, Ferrone CR, Katz MHG, Philip PA, Hong TS, Hackert T, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20:318\u201337.","journal-title":"Nat Rev Clin Oncol"},{"key":"3295_CR77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","volume":"191","author":"H Golcher","year":"2015","unstructured":"Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, et al. Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191:7\u201316.","journal-title":"Strahlenther Onkol"},{"key":"3295_CR78","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","volume":"19","author":"R Casadei","year":"2015","unstructured":"Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L, et al. Neoadjuvant Chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19:1802\u201312.","journal-title":"J Gastrointest Surg"},{"key":"3295_CR79","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","volume":"3","author":"M Reni","year":"2018","unstructured":"Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018;3:413\u201323.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3295_CR80","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38:1763\u201373.","journal-title":"J Clin Oncol"},{"key":"3295_CR81","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial. J Clin Oncol: J Am Soc Clin Oncol. 2022;40:1220\u201330.","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"3295_CR82","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","volume":"7","author":"DPS Sohal","year":"2021","unstructured":"Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7:421\u20137.","journal-title":"JAMA Oncol"},{"key":"3295_CR83","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","volume":"34","author":"T Seufferlein","year":"2023","unstructured":"Seufferlein T, Uhl W, Kornmann M, Algul H, Friess H, Konig A, et al. vgb or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)\u2014a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol: J Eur Soc Med Oncol. 2023;34:91\u2013100.","journal-title":"Ann Oncol: J Eur Soc Med Oncol"},{"key":"3295_CR84","doi-asserted-by":"crossref","unstructured":"Schwarz L, Bachet JB, Meurisse A, Bouch\u00e9 O, Assenat E, Piessen G, et al. Neoadjuvant FOLF(IRIN)OX chemotherapy for resectable pancreatic adenocarcinoma: multicenter randomized noncomparative phase II trial (PANACHE01 FRENCH08 PRODIGE48 study). J Clin Oncol. 2025;43:1984\u201396.","DOI":"10.1200\/JCO-24-01378"},{"key":"3295_CR85","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","volume":"9","author":"KJ Labori","year":"2024","unstructured":"Labori KJ, Bratlie SO, Andersson B, Angelsen JH, Bi\u00f6rserud C, Bj\u00f6rnsson B, et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024;9:205\u201317.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3295_CR86","doi-asserted-by":"crossref","unstructured":"Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP, et al. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial. Lancet Oncol. 2025;26:1346\u201356.","DOI":"10.1016\/j.hpb.2024.03.017"},{"key":"3295_CR87","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1245\/s10434-024-15011-7","volume":"31","author":"TO Goetze","year":"2024","unstructured":"Goetze TO, Reichart A, Bankstahl US, Pauligk C, Loose M, Kraus TW, et al. Adjuvant gemcitabine versus neoadjuvant\/adjuvant FOLFIRINOX in resectable pancreatic cancer: the randomized multicenter phase II NEPAFOX trial. Ann Surg Oncol. 2024;31:4073\u201383.","journal-title":"Ann Surg Oncol"},{"key":"3295_CR88","doi-asserted-by":"publisher","unstructured":"Unno M, Motoi F, Matsuyama Y, Satoi S, Toyama H, Matsumoto I, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer: results of the randomized phase II\/III Prep-02\/JSAP05 trial. Ann Surg. 2025. https:\/\/doi.org\/10.1097\/SLA.0000000000006730.","DOI":"10.1097\/SLA.0000000000006730"},{"key":"3295_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccell.2025.09.009","volume":"43","author":"X Bai","year":"2025","unstructured":"Bai X, Li X, Chen Y, Qiao G, Zhang Q, Ma T, et al. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: a randomized phase 3 trial. Cancer Cell. 2025;43:1\u20139.","journal-title":"Cancer Cell"},{"key":"3295_CR90","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10147-023-02317-x","volume":"28","author":"T Okusaka","year":"2023","unstructured":"Okusaka T, Nakamura M, Yoshida M, Kitano M, Ito Y, Mizuno N, et al. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Int J Clin Oncol. 2023;28:493\u2013511.","journal-title":"Int J Clin Oncol"},{"key":"3295_CR91","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","volume":"27","author":"D Cunningham","year":"2009","unstructured":"Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513\u20138.","journal-title":"J Clin Oncol"},{"key":"3295_CR92","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"3295_CR93","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","volume":"181","author":"M Ozaka","year":"2023","unstructured":"Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer. 2023;181:135\u201344.","journal-title":"Eur J Cancer"},{"key":"3295_CR94","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1200\/JCO-24-02210","volume":"43","author":"M Ducreux","year":"2025","unstructured":"Ducreux M, Desgrippes R, Rinaldi Y, Di Fiore F, Guimbaud R, Evesque L, et al. PRODIGE 29-UCGI 26 (NEOPAN): a phase III randomized trial comparing chemotherapy with FOLFIRINOX or gemcitabine in locally advanced pancreatic carcinoma. J Clin Oncol. 2025;43:2255\u201364.","journal-title":"J Clin Oncol"},{"key":"3295_CR95","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:157\u201368.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3295_CR96","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, Belleau P, Engle DD, Plenker D, Desch\u00eanes A, Somerville TDD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8:1112\u201329.","journal-title":"Cancer Discov"},{"key":"3295_CR97","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1078-0432.CCR-19-1467","volume":"26","author":"NU Rashid","year":"2020","unstructured":"Rashid NU, Peng XL, Jin C, Moffitt RA, Volmar KE, Belt BA, et al. Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer. Clin Cancer Res. 2020;26:82\u201392.","journal-title":"Clin Cancer Res"},{"key":"3295_CR98","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jmoldx.2024.07.002","volume":"26","author":"Y Li","year":"2024","unstructured":"Li Y, Merker JD, Kshatriya R, Trembath DG, Morrison AB, Kuhlers PC, et al. Purity independent subtyping of tumors (purist) pancreatic cancer classifier: analytic validation of a 16-RNA expression signature distinguishing basal and classical subtypes. J Mol Diagn. 2024;26:962\u201370.","journal-title":"J Mol Diagn"},{"key":"3295_CR99","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1158\/1538-7445.AM2024-2542","volume":"84","author":"S Wenric","year":"2024","unstructured":"Wenric S, Davison JM, Guittar J, Mayhew GM, Beebe K, Zander A, et al. Real-world validation of the PurIST classifier demonstrates enhanced therapy selection for pancreatic ductal adenocarcinoma (PDAC) patients. Cancer Res. 2024;84:2542.","journal-title":"Cancer Res"},{"key":"3295_CR100","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.annonc.2020.10.601","volume":"32","author":"R Nicolle","year":"2021","unstructured":"Nicolle R, Gayet O, Duconseil P, Vanbrugghe C, Roques J, Bigonnet M, et al. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Ann Oncol. 2021;32:250\u201360.","journal-title":"Ann Oncol"},{"key":"3295_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101315","volume":"16","author":"R Nicolle","year":"2022","unstructured":"Nicolle R, Gayet O, Bigonnet M, Roques J, Chanez B, Puleo F, et al. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer. Transl Oncol. 2022;16:101315.","journal-title":"Transl Oncol"},{"key":"3295_CR102","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/j.gastro.2022.11.035","volume":"164","author":"N Fraunhoffer","year":"2023","unstructured":"Fraunhoffer N, Chanez B, Teyssedou C. A transcriptomic-based tool to predict gemcitabine sensitivity in advanced pancreatic adenocarcinoma. Gastroenterology. 2023;164:476\u201380.","journal-title":"Gastroenterology"},{"key":"3295_CR103","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1200\/JCO.22.02668","volume":"42","author":"R Nicolle","year":"2024","unstructured":"Nicolle R, Bachet JB, Harl\u00e9 A, Iovanna J, Hammel P, Rebours V, et al. Prediction of adjuvant gemcitabine sensitivity in resectable pancreatic adenocarcinoma using the GemPred RNA signature: an ancillary study of the PRODIGE-24\/CCTG PA6 clinical trial. J Clin Oncol. 2024;42:1067\u201376.","journal-title":"J Clin Oncol"},{"key":"3295_CR104","doi-asserted-by":"publisher","first-page":"997","DOI":"10.21037\/jgo-22-946","volume":"14","author":"D Piquemal","year":"2023","unstructured":"Piquemal D, Bruno R, Bournet B, Ghiringhelli F, Noguier F, Canivet C, et al. Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. J Gastrointest Oncol. 2023;14:997\u20131007.","journal-title":"J Gastrointest Oncol"},{"key":"3295_CR105","doi-asserted-by":"crossref","unstructured":"McLaughlin RM, Jonker DJ, Karanicolas PJ, Ko Y-J, Welch S, Renouf DJ, et al. NeoPancONE: GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): a multicentre phase II study. J Clin Oncology 2025;43:4011.","DOI":"10.1200\/JCO.2025.43.16_suppl.4011"},{"key":"3295_CR106","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","volume":"26","author":"GM O\u2019Kane","year":"2020","unstructured":"O\u2019Kane GM, Gr\u00fcnwald BT, Jang GH, Masoomian M, Picardo S, Grant RC, et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res. 2020;26:4901\u201310. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3724. Epub 2020 Mar 10. Erratum in: Clin Cancer Res. 2022; 28:2715.","journal-title":"Clin Cancer Res"},{"key":"3295_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60808-z","volume":"16","author":"JJ Knox","year":"2025","unstructured":"Knox JJ, Jang GH, Grant RC, Zhang A, Ma L, Elimova E, et al. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Nat Commun. 2025;16:5919.","journal-title":"Nat Commun"},{"key":"3295_CR108","doi-asserted-by":"publisher","first-page":"e473204","DOI":"10.1200\/EDBK-25-473204","volume":"45","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Soares KC, Torphy RJ, Gyawali B. Treatment innovations in pancreatic cancer: putting patient priorities first. Am Soc Clin Oncol Educ Book. 2025;45:e473204.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3295_CR109","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327.","journal-title":"N Engl J Med"},{"key":"3295_CR110","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardi\u00e8re C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402:1272\u201381.","journal-title":"Lancet"},{"key":"3295_CR111","doi-asserted-by":"publisher","first-page":"115051","DOI":"10.1016\/j.ejca.2024.115051","volume":"212","author":"J M\u2019Baloula","year":"2024","unstructured":"M\u2019Baloula J, Tougeron D, Boil\u00e8ve A, Jeanbert E, Guimbaud R, Ben Abdelghani M, et al. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: a French retrospective multicentric AGEO real-world study. Eur J Cancer. 2024;212:115051.","journal-title":"Eur J Cancer"},{"key":"3295_CR112","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1470-2045(23)00516-8","volume":"25","author":"B Gyawali","year":"2024","unstructured":"Gyawali B, Booth CM. Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients. Lancet Oncol. 2024;25:167\u201370.","journal-title":"Lancet Oncol"},{"key":"3295_CR113","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/S1470-2045(24)00451-0","volume":"26","author":"B Gyawali","year":"2025","unstructured":"Gyawali B, Eisenhauer EA, van der Graaf W, Booth CM, Cherny NI, Goodman AM, et al. Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials. Lancet Oncol. 2025;26:e80\u2013e89.","journal-title":"Lancet Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03295-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03295-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03295-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:03:12Z","timestamp":1769774592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03295-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,20]]}},"alternative-id":["3295"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03295-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CS declares advisory board membership for Astra Zeneca, Bayer, BMS, Roche, Incyte, MSD, Revolution Medicines, Servier and Taiho. DHP declares advisory board membership and consultancy for MSD, BMS, AZ, Sirtex, Taiho, Jazz, Viatris, Nucana, Medannex, Servier, and Pfizer; Research Grant Funding from BMS, Sirtex, Nucana, and Medannex. JPN declares advisory board membership for BioNTech (BNT32), and the patent 52378-704.601 PCT 23 May 2025, Combination of Irinotecan and AP-001 for treating cancer. T. Hackert, D\u00d6, TP, T. Hank, MWB and CWM declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All of the authors approved the final manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}